Glycaemic control, body weight, and safety of tirzepatide versus dulaglutide by baseline glycated haemoglobin level in Japanese patients with type 2 diabetes: A subgroup analysis of the SURPASS J-mono study.

Osonoi T, Oura T, Hirase T

Diabetes, obesity & metabolism4 Oct 2023Cited by 2 (Europe PMC)

PMID37794628DOI10.1111/dom.15296PepBankPUB-37794628

Read at source PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study16

13 results from studies that gave the peptide. 13 results from people.

01HumanRandomized controlled trialEfficacy outcome
In Japanese adults with type 2 diabetes, HbA1c reductions with tirzepatide were greater in those with baseline HbA1c above 8.5% (LSM differences -3.13% to -3.86%) than in those with baseline HbA1c of 8.5% or lower (-2.00% to -2.32%), with a significant treatment-by-baseline HbA1c interaction (P <= 0.001).
In plain wordsIn Japanese adults with type 2 diabetes, tirzepatide lowered HbA1c more in people who started with higher HbA1c than in people who started lower.
Peptide
Tirzepatide
Outcome
DecreaseHbA1c reduction by baseline HbA1c subgroup (interaction)
Study
n = 636
Comparator
Baseline HbA1c <=8.5% subgroup
Analysis
Exploratory
Outcome group
Glycemic control · Metabolic and weight
Studied dose
5, 10 or 15 mg · 52 weeksAs given in this study (human).
Source sentences
Summary
with greater HbA1c reductions observed in patients with a baseline HbA1c of >8.5% treated with tirzepatide (least squares mean [LSM] differences of -3.13% to -3.86%) or dulaglutide (LSM -1.81%) compared with patients with a baseline HbA1c of ≤8.5% (LSM -2.00% to -2.32%) or dulaglutide (LSM -1.05%; t…
1 context sentence(design, population, supporting numbers)
Summary · context
In this exploratory subgroup analysis of SURPASS J-mono, we examined mean change in HbA1c and body weight and the incidence of adverse events (AEs) in patients with a baseline HbA1c of ≤8.5% versus >8.5% after treatment with tirzepatide (5, 10 or 15 mg) or dulaglutide 0.75 mg.
Report a problemFND-3779462807
02HumanRandomized controlled trialEfficacy outcome
In Japanese patients with T2D, dulaglutide reduced HbA1c less than any-dose tirzepatide in both baseline HbA1c subgroups.
In plain wordsIn Japanese patients with diabetes, dulaglutide reduced HbA1c less than tirzepatide in both initial blood sugar subgroups.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseHbA1c reduction versus tirzepatide
Study
n = 636
Comparator
Any-dose tirzepatide in each baseline HbA1c subgroup
Analysis
Exploratory
Outcome group
Glycemic control · Metabolic and weight
Studied dose
0.75 mg · 52 weeksAs given in this study (human).
Source sentences
Summary
Both subgroups showed significantly greater reductions in HbA1c and body weight with any-dose tirzepatide versus dulaglutide 0.75 mg
2 context sentences(design, population, supporting numbers)
Summary · context
SURPASS J-mono was a 52-week, multicentre, randomized, double-blind, parallel, active-controlled, phase 3 study conducted in Japan.
Summary · context
In this exploratory subgroup analysis of SURPASS J-mono, we examined mean change in HbA1c and body weight and the incidence of adverse events (AEs) in patients with a baseline HbA1c of ≤8.5% versus >8.5% after treatment with tirzepatide (5, 10 or 15 mg) or dulaglutide 0.75 mg.
Report a problemFND-3779462808
03HumanRandomized controlled trialEfficacy outcome
In Japanese patients with T2D, dulaglutide reduced body weight less than any-dose tirzepatide in both baseline HbA1c subgroups.
In plain wordsIn Japanese patients with diabetes, dulaglutide reduced weight less than tirzepatide in both initial blood sugar subgroups.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseBody weight reduction versus tirzepatide
Study
n = 636
Comparator
Any-dose tirzepatide in each baseline HbA1c subgroup
Analysis
Exploratory
Outcome group
Body weight · Metabolic and weight
Studied dose
0.75 mg · 52 weeksAs given in this study (human).
Source sentences
Summary
Both subgroups showed significantly greater reductions in HbA1c and body weight with any-dose tirzepatide versus dulaglutide 0.75 mg
2 context sentences(design, population, supporting numbers)
Summary · context
SURPASS J-mono was a 52-week, multicentre, randomized, double-blind, parallel, active-controlled, phase 3 study conducted in Japan.
Summary · context
In this exploratory subgroup analysis of SURPASS J-mono, we examined mean change in HbA1c and body weight and the incidence of adverse events (AEs) in patients with a baseline HbA1c of ≤8.5% versus >8.5% after treatment with tirzepatide (5, 10 or 15 mg) or dulaglutide 0.75 mg.
Report a problemFND-3779462812
04HumanRandomized controlled trialEfficacy outcome
In Japanese adults with type 2 diabetes and baseline HbA1c of 8.5% or lower, tirzepatide at any dose reduced HbA1c significantly more than dulaglutide 0.75 mg.
In plain wordsIn Japanese adults with type 2 diabetes and lower starting HbA1c, tirzepatide lowered HbA1c more than dulaglutide did.
Peptide
Tirzepatide
Outcome
DecreaseHbA1c reduction, baseline HbA1c <=8.5% subgroup
Study
n = 433
Comparator
Dulaglutide 0.75 mg
Analysis
Exploratory
Outcome group
Glycemic control · Metabolic and weight
Studied dose
5, 10 or 15 mg · 52 weeksAs given in this study (human).
Source sentences
Summary
Both subgroups showed significantly greater reductions in HbA1c and body weight with any-dose tirzepatide versus dulaglutide 0.75 mg
3 context sentences(design, population, supporting numbers)
Summary · context
compared with patients with a baseline HbA1c of ≤8.5% (LSM -2.00% to -2.32%) or dulaglutide (LSM -1.05%
Summary · context
SURPASS J-mono was a 52-week, multicentre, randomized, double-blind, parallel, active-controlled, phase 3 study conducted in Japan.
Summary · context
In this exploratory subgroup analysis of SURPASS J-mono, we examined mean change in HbA1c and body weight and the incidence of adverse events (AEs) in patients with a baseline HbA1c of ≤8.5% versus >8.5% after treatment with tirzepatide (5, 10 or 15 mg) or dulaglutide 0.75 mg.
Report a problemFND-3779462802
05HumanRandomized controlled trialEfficacy outcome
In Japanese adults with type 2 diabetes and baseline HbA1c of 8.5% or lower, tirzepatide changed body weight by -6.7 to -10.7 kg across doses, versus -0.6 kg with dulaglutide 0.75 mg.
In plain wordsIn Japanese adults with type 2 diabetes and lower starting HbA1c, tirzepatide reduced body weight more than dulaglutide did.
Peptide
Tirzepatide
Outcome
DecreaseBody weight change, baseline HbA1c <=8.5% subgroup
Study
n = 433
Comparator
Dulaglutide 0.75 mg
Analysis
Exploratory
Outcome group
Body weight · Metabolic and weight
Studied dose
5, 10 or 15 mg · 52 weeksAs given in this study (human).
Source sentences
Summary
For the tirzepatide treatment arms, LSM change from baseline in body weight ranged from -6.7 to -10.7 kg for the baseline HbA1c ≤8.5% subgroup and from -4.0 to -10.6 kg for the baseline HbA1c >8.5% subgroup, compared with -0.6 kg and -0.4 kg, respectively, for the dulaglutide arm.
3 context sentences(design, population, supporting numbers)
Summary · context
Both subgroups showed significantly greater reductions in HbA1c and body weight with any-dose tirzepatide versus dulaglutide 0.75 mg
Summary · context
SURPASS J-mono was a 52-week, multicentre, randomized, double-blind, parallel, active-controlled, phase 3 study conducted in Japan.
Summary · context
In this exploratory subgroup analysis of SURPASS J-mono, we examined mean change in HbA1c and body weight and the incidence of adverse events (AEs) in patients with a baseline HbA1c of ≤8.5% versus >8.5% after treatment with tirzepatide (5, 10 or 15 mg) or dulaglutide 0.75 mg.
Report a problemFND-3779462804
06HumanRandomized controlled trialEfficacy outcome
In Japanese adults with type 2 diabetes and baseline HbA1c above 8.5%, tirzepatide at any dose reduced HbA1c significantly more than dulaglutide 0.75 mg.
In plain wordsIn Japanese adults with type 2 diabetes and high starting HbA1c, tirzepatide lowered HbA1c more than dulaglutide did.
Peptide
Tirzepatide
Outcome
DecreaseHbA1c reduction, baseline HbA1c >8.5% subgroup
Study
n = 203
Comparator
Dulaglutide 0.75 mg
Analysis
Exploratory
Outcome group
Glycemic control · Metabolic and weight
Studied dose
5, 10 or 15 mg · 52 weeksAs given in this study (human).
Source sentences
Summary
Both subgroups showed significantly greater reductions in HbA1c and body weight with any-dose tirzepatide versus dulaglutide 0.75 mg
3 context sentences(design, population, supporting numbers)
Summary · context
with greater HbA1c reductions observed in patients with a baseline HbA1c of >8.5% treated with tirzepatide (least squares mean [LSM] differences of -3.13% to -3.86%) or dulaglutide (LSM -1.81%)
Summary · context
SURPASS J-mono was a 52-week, multicentre, randomized, double-blind, parallel, active-controlled, phase 3 study conducted in Japan.
Summary · context
In this exploratory subgroup analysis of SURPASS J-mono, we examined mean change in HbA1c and body weight and the incidence of adverse events (AEs) in patients with a baseline HbA1c of ≤8.5% versus >8.5% after treatment with tirzepatide (5, 10 or 15 mg) or dulaglutide 0.75 mg.
Report a problemFND-3779462801
07HumanRandomized controlled trialEfficacy outcome
In Japanese adults with type 2 diabetes and baseline HbA1c above 8.5%, tirzepatide changed body weight by -4.0 to -10.6 kg across doses, versus -0.4 kg with dulaglutide 0.75 mg.
In plain wordsIn Japanese adults with type 2 diabetes and high starting HbA1c, tirzepatide reduced body weight more than dulaglutide did.
Peptide
Tirzepatide
Outcome
DecreaseBody weight change, baseline HbA1c >8.5% subgroup
Study
n = 203
Comparator
Dulaglutide 0.75 mg
Analysis
Exploratory
Outcome group
Body weight · Metabolic and weight
Studied dose
5, 10 or 15 mg · 52 weeksAs given in this study (human).
Source sentences
Summary
For the tirzepatide treatment arms, LSM change from baseline in body weight ranged from -6.7 to -10.7 kg for the baseline HbA1c ≤8.5% subgroup and from -4.0 to -10.6 kg for the baseline HbA1c >8.5% subgroup, compared with -0.6 kg and -0.4 kg, respectively, for the dulaglutide arm.
3 context sentences(design, population, supporting numbers)
Summary · context
Both subgroups showed significantly greater reductions in HbA1c and body weight with any-dose tirzepatide versus dulaglutide 0.75 mg
Summary · context
SURPASS J-mono was a 52-week, multicentre, randomized, double-blind, parallel, active-controlled, phase 3 study conducted in Japan.
Summary · context
In this exploratory subgroup analysis of SURPASS J-mono, we examined mean change in HbA1c and body weight and the incidence of adverse events (AEs) in patients with a baseline HbA1c of ≤8.5% versus >8.5% after treatment with tirzepatide (5, 10 or 15 mg) or dulaglutide 0.75 mg.
Report a problemFND-3779462803
08HumanRandomized controlled trialEfficacy outcome
In Japanese patients with T2D and baseline HbA1c above 8.5%, dulaglutide reduced HbA1c from baseline.
In plain wordsIn Japanese patients with diabetes and higher initial HbA1c, dulaglutide reduced HbA1c from baseline.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseHbA1c change, higher baseline HbA1c subgroup
Study
n: not reported in source
Comparator
Baseline
Analysis
Exploratory
Outcome group
Glycemic control · Metabolic and weight
Studied dose
0.75 mg · 52 weeksAs given in this study (human).
Measurements
HbA1c LSM change
−1.81%
dulaglutide; baseline HbA1c >8.5%
Source sentences
Summary
with greater HbA1c reductions observed in patients with a baseline HbA1c of >8.5% treated with tirzepatide (least squares mean [LSM] differences of -3.13% to -3.86%) or dulaglutide (LSM -1.81%)
2 context sentences(design, population, supporting numbers)
Summary · context
SURPASS J-mono was a 52-week, multicentre, randomized, double-blind, parallel, active-controlled, phase 3 study conducted in Japan.
Summary · context
In this exploratory subgroup analysis of SURPASS J-mono, we examined mean change in HbA1c and body weight and the incidence of adverse events (AEs) in patients with a baseline HbA1c of ≤8.5% versus >8.5% after treatment with tirzepatide (5, 10 or 15 mg) or dulaglutide 0.75 mg.
Report a problemFND-3779462809
09HumanRandomized controlled trialEfficacy outcome
In Japanese patients with T2D and baseline HbA1c at most 8.5%, dulaglutide reduced HbA1c from baseline.
In plain wordsIn Japanese patients with diabetes and lower initial HbA1c, dulaglutide reduced HbA1c from baseline.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseHbA1c change, lower baseline HbA1c subgroup
Study
n: not reported in source
Comparator
Baseline
Analysis
Exploratory
Outcome group
Glycemic control · Metabolic and weight
Studied dose
0.75 mg · 52 weeksAs given in this study (human).
Measurements
HbA1c LSM change
−1.05%
dulaglutide; baseline HbA1c ≤8.5%
Source sentences
Summary
compared with patients with a baseline HbA1c of ≤8.5% (LSM -2.00% to -2.32%) or dulaglutide (LSM -1.05%; treatment-by-baseline HbA1c subgroup interaction P ≤ 0.001).
2 context sentences(design, population, supporting numbers)
Summary · context
SURPASS J-mono was a 52-week, multicentre, randomized, double-blind, parallel, active-controlled, phase 3 study conducted in Japan.
Summary · context
In this exploratory subgroup analysis of SURPASS J-mono, we examined mean change in HbA1c and body weight and the incidence of adverse events (AEs) in patients with a baseline HbA1c of ≤8.5% versus >8.5% after treatment with tirzepatide (5, 10 or 15 mg) or dulaglutide 0.75 mg.
Report a problemFND-3779462810
10HumanRandomized controlled trialEfficacy outcome
In Japanese patients with T2D and baseline HbA1c at most 8.5%, dulaglutide reduced body weight from baseline.
In plain wordsIn Japanese patients with diabetes and lower initial HbA1c, body weight decreased during dulaglutide treatment.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseBody weight change, lower baseline HbA1c subgroup
Study
n: not reported in source
Comparator
Baseline
Analysis
Exploratory
Outcome group
Body weight · Metabolic and weight
Studied dose
0.75 mg · 52 weeksAs given in this study (human).
Measurements
Body weight LSM change
−0.6 kg
dulaglutide; baseline HbA1c ≤8.5%
Source sentences
Summary
For the tirzepatide treatment arms, LSM change from baseline in body weight ranged from -6.7 to -10.7 kg for the baseline HbA1c ≤8.5% subgroup and from -4.0 to -10.6 kg for the baseline HbA1c >8.5% subgroup, compared with -0.6 kg and -0.4 kg, respectively, for the dulaglutide arm.
2 context sentences(design, population, supporting numbers)
Summary · context
SURPASS J-mono was a 52-week, multicentre, randomized, double-blind, parallel, active-controlled, phase 3 study conducted in Japan.
Summary · context
In this exploratory subgroup analysis of SURPASS J-mono, we examined mean change in HbA1c and body weight and the incidence of adverse events (AEs) in patients with a baseline HbA1c of ≤8.5% versus >8.5% after treatment with tirzepatide (5, 10 or 15 mg) or dulaglutide 0.75 mg.
Report a problemFND-3779462813
11HumanRandomized controlled trialEfficacy outcome
In Japanese patients with T2D and baseline HbA1c above 8.5%, dulaglutide reduced body weight from baseline.
In plain wordsIn Japanese patients with diabetes and higher initial HbA1c, body weight decreased during dulaglutide treatment.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseBody weight change, higher baseline HbA1c subgroup
Study
n: not reported in source
Comparator
Baseline
Analysis
Exploratory
Outcome group
Body weight · Metabolic and weight
Studied dose
0.75 mg · 52 weeksAs given in this study (human).
Measurements
Body weight LSM change
−0.4 kg
dulaglutide; baseline HbA1c >8.5%
Source sentences
Summary
For the tirzepatide treatment arms, LSM change from baseline in body weight ranged from -6.7 to -10.7 kg for the baseline HbA1c ≤8.5% subgroup and from -4.0 to -10.6 kg for the baseline HbA1c >8.5% subgroup, compared with -0.6 kg and -0.4 kg, respectively, for the dulaglutide arm.
2 context sentences(design, population, supporting numbers)
Summary · context
SURPASS J-mono was a 52-week, multicentre, randomized, double-blind, parallel, active-controlled, phase 3 study conducted in Japan.
Summary · context
In this exploratory subgroup analysis of SURPASS J-mono, we examined mean change in HbA1c and body weight and the incidence of adverse events (AEs) in patients with a baseline HbA1c of ≤8.5% versus >8.5% after treatment with tirzepatide (5, 10 or 15 mg) or dulaglutide 0.75 mg.
Report a problemFND-3779462814
12HumanObservational studySafety outcome
In Japanese adults with type 2 diabetes, hypoglycaemia incidence was low, with no substantial difference between the baseline HbA1c subgroups.
In plain wordsIn Japanese adults with type 2 diabetes, low blood sugar was uncommon and did not differ much between the two starting-HbA1c groups.
Peptide
Tirzepatide
Outcome
No significant changeHypoglycaemia incidence between baseline HbA1c subgroups
Study
n = 636
Comparator
Baseline HbA1c >8.5% versus <=8.5% subgroups
Analysis
Exploratory
Outcome group
Adverse events · Metabolic and weight
Studied dose
5, 10 or 15 mg · 52 weeksAs given in this study (human).
Source sentences
Summary
The incidence of hypoglycaemia was low, with no substantial difference in hypoglycaemia or treatment-emergent AEs between subgroups.
2 context sentences(design, population, supporting numbers)
Summary · context
SURPASS J-mono was a 52-week, multicentre, randomized, double-blind, parallel, active-controlled, phase 3 study conducted in Japan.
Summary · context
In this exploratory subgroup analysis of SURPASS J-mono, we examined mean change in HbA1c and body weight and the incidence of adverse events (AEs) in patients with a baseline HbA1c of ≤8.5% versus >8.5% after treatment with tirzepatide (5, 10 or 15 mg) or dulaglutide 0.75 mg.
Report a problemFND-3779462805
13HumanObservational studySafety outcome
In Japanese adults with type 2 diabetes, treatment-emergent adverse events showed no substantial difference between the baseline HbA1c subgroups.
In plain wordsIn Japanese adults with type 2 diabetes, side effects did not differ much between the two starting-HbA1c groups.
Peptide
Tirzepatide
Outcome
No significant changeTreatment-emergent adverse events between baseline HbA1c subgroups
Study
n = 636
Comparator
Baseline HbA1c >8.5% versus <=8.5% subgroups
Analysis
Exploratory
Outcome group
Adverse events · Metabolic and weight
Studied dose
5, 10 or 15 mg · 52 weeksAs given in this study (human).
Source sentences
Summary
The incidence of hypoglycaemia was low, with no substantial difference in hypoglycaemia or treatment-emergent AEs between subgroups.
2 context sentences(design, population, supporting numbers)
Summary · context
SURPASS J-mono was a 52-week, multicentre, randomized, double-blind, parallel, active-controlled, phase 3 study conducted in Japan.
Summary · context
In this exploratory subgroup analysis of SURPASS J-mono, we examined mean change in HbA1c and body weight and the incidence of adverse events (AEs) in patients with a baseline HbA1c of ≤8.5% versus >8.5% after treatment with tirzepatide (5, 10 or 15 mg) or dulaglutide 0.75 mg.
Report a problemFND-3779462806

Studies that did not test the peptide alone3

In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Dulaglutide (Trulicity).

14HumanNot a test of Dulaglutide (Trulicity) aloneObservational studySafety outcome
In Japanese patients with T2D, pooled tirzepatide and dulaglutide results showed low hypoglycaemia incidence without substantial baseline-subgroup differences.
In plain wordsIn Japanese patients with diabetes, pooled dulaglutide and tirzepatide results showed low hypoglycaemia rates and no substantial differences between initial HbA1c subgroups.
Peptide
Dulaglutide (Trulicity)
Outcome
No significant changeHypoglycaemia incidence
Study
n = 636
Comparator
Baseline HbA1c subgroups
Analysis
Exploratory
Outcome group
Adverse events · Metabolic and weight
Source sentences
Summary
The incidence of hypoglycaemia was low, with no substantial difference in hypoglycaemia or treatment-emergent AEs between subgroups.
2 context sentences(design, population, supporting numbers)
Summary · context
SURPASS J-mono was a 52-week, multicentre, randomized, double-blind, parallel, active-controlled, phase 3 study conducted in Japan.
Summary · context
In this exploratory subgroup analysis of SURPASS J-mono, we examined mean change in HbA1c and body weight and the incidence of adverse events (AEs) in patients with a baseline HbA1c of ≤8.5% versus >8.5% after treatment with tirzepatide (5, 10 or 15 mg) or dulaglutide 0.75 mg.
In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).
Report a problemFND-3779462815
15HumanNot a test of Dulaglutide (Trulicity) aloneObservational studySafety outcome
In Japanese patients with T2D, pooled tirzepatide and dulaglutide results showed no substantial baseline-subgroup difference in treatment-emergent adverse events.
In plain wordsIn Japanese patients with diabetes, pooled dulaglutide and tirzepatide results showed no substantial difference in adverse events between initial HbA1c subgroups.
Peptide
Dulaglutide (Trulicity)
Outcome
No significant changeTreatment-emergent adverse events
Study
n = 636
Comparator
Baseline HbA1c subgroups
Analysis
Exploratory
Outcome group
Adverse events · Whole body
Source sentences
Summary
The incidence of hypoglycaemia was low, with no substantial difference in hypoglycaemia or treatment-emergent AEs between subgroups.
2 context sentences(design, population, supporting numbers)
Summary · context
SURPASS J-mono was a 52-week, multicentre, randomized, double-blind, parallel, active-controlled, phase 3 study conducted in Japan.
Summary · context
In this exploratory subgroup analysis of SURPASS J-mono, we examined mean change in HbA1c and body weight and the incidence of adverse events (AEs) in patients with a baseline HbA1c of ≤8.5% versus >8.5% after treatment with tirzepatide (5, 10 or 15 mg) or dulaglutide 0.75 mg.
In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).
Report a problemFND-3779462816
16HumanNot a test of Dulaglutide (Trulicity) aloneObservational studyEfficacy outcome
In Japanese patients with T2D receiving dulaglutide, higher baseline HbA1c was associated with a larger HbA1c reduction.
In plain wordsIn Japanese patients with diabetes receiving dulaglutide, higher initial HbA1c was linked to a larger HbA1c decrease.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseHbA1c reduction by baseline subgroup
Study
n: not reported in source
Comparator
Dulaglutide-treated patients with baseline HbA1c ≤8.5%
Analysis
Exploratory
Outcome group
Glycemic control · Metabolic and weight
Measurements
HbA1c LSM change
−1.81%
dulaglutide; baseline HbA1c >8.5%
HbA1c LSM change
−1.05%
dulaglutide; baseline HbA1c ≤8.5%
Source sentences
Summary
with greater HbA1c reductions observed in patients with a baseline HbA1c of >8.5% treated with tirzepatide (least squares mean [LSM] differences of -3.13% to -3.86%) or dulaglutide (LSM -1.81%)
3 context sentences(design, population, supporting numbers)
Summary · context
compared with patients with a baseline HbA1c of ≤8.5% (LSM -2.00% to -2.32%) or dulaglutide (LSM -1.05%; treatment-by-baseline HbA1c subgroup interaction P ≤ 0.001).
Summary · context
SURPASS J-mono was a 52-week, multicentre, randomized, double-blind, parallel, active-controlled, phase 3 study conducted in Japan.
Summary · context
In this exploratory subgroup analysis of SURPASS J-mono, we examined mean change in HbA1c and body weight and the incidence of adverse events (AEs) in patients with a baseline HbA1c of ≤8.5% versus >8.5% after treatment with tirzepatide (5, 10 or 15 mg) or dulaglutide 0.75 mg.
In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).
Report a problemFND-3779462811

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Versions 4 to 8Current
28 Oct 2026, 02:03 UTC
The same notice was added 5 times, first on 22 Oct 2026, 02:26 UTC. The status did not change between them.
Study results updated
Version 3
21 Oct 2026, 18:59 UTC
Study data updated · source update from Europe PMC
Version 2
12 Oct 2026, 12:58 UTC
Study results updated
Version 1
9 Oct 2026, 03:07 UTC
First added · source update from Europe PMC

PepBank is a research reference. Talk to a doctor before you use any peptide.

Glycaemic control, body weight, and safety of tirzepatide versus dulaglutide by baseline glycated haemoglobin level in Japanese patients with type 2 diabetes: A subgroup analysis of the SURPASS J-mono study.

Summary

Results from this study16

Studies that did not test the peptide alone3

Version history

Subjects

Publication types

MeSH terms

Keywords